Company overview
MeMed develops host-immune response diagnostics, including the FDA-cleared MeMed BV test that distinguishes bacterial from viral infections in 15 minutes using serum or whole blood on the compact MeMed Key platform. The test measures immune proteins like TRAIL, IP-10, and CRP with machine learning for actionable scores, aiding antibiotic stewardship and reducing antimicrobial resistance. Additional products like MeMed BV Flex (FDA Breakthrough Designation for capillary blood) and MeMed Severity (for predicting severe outcomes) expand point-of-care capabilities in hospitals and decentralized settings.
Industry categories: CRO & Clinical Services, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.me-med.com
- Categories
- CRO & Clinical Services, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- memed bv, host immune response, bacterial viral test, fda cleared diagnostics, antimicrobial stewardship
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What regulatory approvals does MeMed BV have?
- MeMed BV is FDA-cleared and CE-marked for differentiating bacterial from viral infections in 15 minutes from serum or venous whole blood.
- What sample types and platforms does MeMed use?
- MeMed BV uses serum or venous whole blood on the FDA-cleared MeMed Key platform; MeMed BV Flex (investigational) uses capillary blood for point-of-care in hospitals and CLIA-waived settings.
- What clinical validation supports MeMed's tests?
- MeMed BV performance is validated in multinational, double-blind studies and real-world use on nearly 20,000 patients across Europe, Israel, and the US, covering diverse bacterial and viral pathogens.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
